CeleCor Therapeutics, Inc.

CeleCor Therapeutics, Inc. has raised $63.3M in total funding. The most recent round was Series A.

CeleCor Therapeutics, Inc. is headquartered in Del Mar, CA.

There is a time-to-treatment gap for the 800,000 people in the U.S. who have a heart attack (STEMI) each year, since effective treatment isn't available at the first point of medical contact before reaching a hospital.

CeleCor is developing zalunfiban, an investigational subcutaneously-injected platelet inhibitor for pre-hospital treatment of STEMI heart attacks, across multiple pre-PCI settings.

Zalunfiban is a next-generation GPIIb/IIIa platelet inhibitor engineered to reach maximal effect within 15 minutes of injection while its antiplatelet effect wears off in about two hours.

Co-founded by biomedical engineer Robert S. Hillman, PhD; developing devices/therapies to get STEMI heart-attack patients to treatment with open coronary arteries, and has raised $58.4M.